Liquid biopsy in pancreatic cancer: current advances, limitations, and future perspectives - PubMed
5 hours ago
- #Liquid Biopsy
- #PDAC
- #Pancreatic Cancer
- Pancreatic ductal adenocarcinoma (PDAC) is the most common pancreatic malignancy, often diagnosed at advanced stages.
- Current diagnosis relies on endoscopic ultrasound-guided tissue biopsy, which may not always provide sufficient material for molecular analysis.
- Liquid biopsy (LB) offers a minimally invasive alternative for biomarker analysis, improving diagnosis, prognosis, and disease monitoring.
- Key biomarkers detected via LB include circulating tumor cells (CTCs), cell-free DNA (cfDNA), circulating miRNA, and extracellular vesicles.
- Despite its potential, no LB assay is yet validated for routine PDAC management, but multimodal integration may soon reshape diagnostic strategies.